47 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO http://www.zacks.com/stock/news/1061064/novartis-announces-data-on-tafinlar-mekinist-piqray-at-esmo?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-1061064 Sep 21, 2020 - Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.
Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma http://www.zacks.com/stock/news/845181/novartis-reports-data-on-inclisiran-chmp-positive-on-zolgensma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845181 Mar 30, 2020 - Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children http://www.zacks.com/stock/news/847430/lillys-taltz-gets-fda-nod-for-plaque-psoriasis-in-children?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-847430 Mar 31, 2020 - The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
Top Stock Reports for J&J, Merck, Novartis & Others http://www.zacks.com/research-daily/857167/top-stock-reports-for-jj-merck-novartis-others?cid=CS-ZC-FT-research_daily-857167 Apr 06, 2020 - Top Stock Reports for J&J, Merck, Novartis & Others
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress http://www.zacks.com/stock/news/859545/biotech-stocks-etfs-to-gain-on-covid-19-vaccine-drug-progress?cid=CS-ZC-FT-etf_news_and_commentary-859545 Apr 07, 2020 - The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Roche's NDA for SMA Drug Gets Expanded Review From FDA http://www.zacks.com/stock/news/861186/roches-nda-for-sma-drug-gets-expanded-review-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-861186 Apr 08, 2020 - The FDA stretches the review timeline of Roche's (RHHBY) NDA for risdiplam by three months, which is being evaluated to treat spinal muscular atrophy. A decision is now pending on Aug 24, 2020.
Incyte Gets FDA Nod for Cholangiocarcinoma Drug Pemazyre http://www.zacks.com/stock/news/880319/incyte-gets-fda-nod-for-cholangiocarcinoma-drug-pemazyre?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-880319 Apr 20, 2020 - Incyte (INCY) gets FDA approval for Pemazyre for the treatment of previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma.
Alexion to Evaluate Rare Disease Drug for COVID-19, Shares Up http://www.zacks.com/stock/news/882015/alexion-to-evaluate-rare-disease-drug-for-covid-19-shares-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-882015 Apr 21, 2020 - Alexion (ALXN) gains as it announces plans to initiate a study to evaluate Ultomiris for the COVID-19 infection.
Roche (RHHBY) Q1 Sales Grow on Solid Performance of New Drugs http://www.zacks.com/stock/news/883666/roche-rhhby-q1-sales-grow-on-solid-performance-of-new-drugs?cid=CS-ZC-FT-analyst_blog|earnings_article-883666 Apr 22, 2020 - Solid sales of Roche's (RHHBY) new drugs in the first quarter more than offset the competition from biosimilars.
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-887364 Apr 24, 2020 - Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.

Pages: 12345

<<<Page 4